Lacosamide Dosing Guidelines
Lacosamide dosing in adults typically starts at 100 mg/day with weekly titration by 100 mg/day increments to a target maintenance dose of 200-400 mg/day in two divided doses, with a maximum of 600 mg/day; pediatric dosing requires body surface area (BSA)-based adjustments, and renal impairment necessitates dose reductions of approximately 25-75% depending on severity.
Adult Dosing
Standard Dosing Regimen
- Starting dose: 100 mg/day (50 mg twice daily)
- Titration: Increase by 100 mg/day weekly as tolerated 1
- Target maintenance: 200-400 mg/day in two divided doses
- Maximum dose: 600 mg/day 1
The 400 mg/day dose provides optimal balance between efficacy and tolerability, while 600 mg/day may offer additional benefit for some patients, particularly those with secondarily generalized tonic-clonic seizures 1. At 400 mg/day, median seizure frequency reduction is 37.3% with a 38.3% responder rate; at 600 mg/day, reduction is 37.8% with 41.2% responder rate 1.
Renal Impairment Adjustments
Dose reductions are mandatory for moderate-to-severe renal impairment 2:
- Mild impairment (CrCl 50-80 mL/min): Reduce to ~82% of standard dose 3
- Moderate impairment (CrCl 30-50 mL/min): Reduce to ~75% of standard dose 3
- Severe impairment (CrCl <30 mL/min): Reduce to ~63% of standard dose 3
- End-stage renal disease (ESRD): Reduce to ~76% of standard dose 3
For patients on hemodialysis, approximately 50% of lacosamide is removed during a 4-hour session 2. Supplemental dosing after hemodialysis should be considered, typically 50% of the regular dose 2.
In critically ill patients receiving continuous renal replacement therapy (CRRT), optimal dosing is 300-450 mg/day for effluent rates of 20-25 mL/kg/h, increasing to 600 mg/day for higher effluent rates of 35 mL/kg/h 4.
Pediatric Dosing
Intravenous Dosing (BSA-based)
Age-specific weight-based dosing 3:
- Newborns: 1.75 mg/kg
- Toddlers: 2.5 mg/kg
- Preschool and school age: 2.2 mg/kg
- Adolescents: 2 mg/kg
Oral Dosing (Fixed doses for equivalent exposure)
Age-specific fixed doses to achieve equivalent plasma exposure to 100 mg in adults 3:
- Toddlers: 20 mg
- Preschool: 32 mg
- School age: 45 mg
- Adolescents: 95 mg
Body Weight Band Dosing
A simplified approach using body weight bands is clinically viable 5. For patients ≥10 kg, a fixed 100 mg dose achieves equivalent exposure to body weight-adjusted dosing 5. This approach maintains >78% target attainment and is particularly practical for children aged 1-4 years and obese patients 5.
Pediatric Renal Impairment
Apply the same percentage reductions as adults based on creatinine clearance 3.
Special Populations
Hepatic Impairment
Dose reductions required 3:
- Child-Pugh A: Reduce to ~89% of standard dose
- Child-Pugh B: Reduce to ~72% of standard dose
- Child-Pugh C: Reduce to ~36% of standard dose
Elevated Uric Acid
Patients with uric acid >400 μmol/L should receive half the dose compared to those with uric acid of 100 μmol/L 6. This represents a clinically significant covariate affecting lacosamide clearance in pediatric patients.
Obese Patients
Patients with body weight >100 kg are less likely to attain therapeutic targets 4. Consider higher end of dosing range or therapeutic drug monitoring.
Contraindications and Precautions
Absolute Contraindications
- Second- or third-degree atrioventricular block (lacosamide affects cardiac conduction)
- Known hypersensitivity to lacosamide
Relative Contraindications
- Cardiac conduction abnormalities: Use with caution; baseline and periodic ECG monitoring recommended
- Severe hepatic impairment (Child-Pugh C): Use only if benefits outweigh risks with substantial dose reduction 3
Drug Interactions
Lacosamide has minimal drug interactions. Unlike other antiepileptic drugs, valproic acid, levetiracetam, oxcarbazepine, lamotrigine, and perampanel do not significantly affect lacosamide pharmacokinetics 6. CYP2C19, ABCB1, and ABCC2 gene polymorphisms also lack clinical significance 6, though CYP2C19 genotyping may enhance precision in some cases 5.
Therapeutic Drug Monitoring
Target trough concentrations: 5-10 mg/L 4
Target AUC: 80.25-231 mg·h/L for initial 72-hour therapy 4
Therapeutic drug monitoring is particularly important in:
- Neonates (off-label use) where doses up to 22 mg/kg/day in 4 divided doses may be needed 7
- Patients with renal impairment
- Critically ill patients on CRRT 4
- Patients with elevated uric acid 6
Missed or Delayed Doses
Individualized remedial doses of 0.5- to 1.5-fold the regular dose are recommended, depending on the delayed time 6. The specific remedial dose should be calculated based on how long the dose was delayed to maintain therapeutic concentrations.
Common Pitfalls
- Underestimating renal impairment: Serum creatinine may appear normal in elderly patients despite significant GFR reduction; always calculate creatinine clearance
- Inadequate dose reduction in renal impairment: Failure to adjust doses in moderate-to-severe renal impairment increases adverse event risk
- Forgetting hemodialysis supplementation: 50% drug removal necessitates post-dialysis dosing
- Overlooking cardiac monitoring: Lacosamide can prolong PR interval; baseline ECG is essential